Scleroderma Clinical Trial Pipeline Analysis: 25+ Key Companies Advancing Next-Generation Therapies for Systemic Sclerosis Treatment | DelveInsight

DelveInsight's "Scleroderma Pipeline Insight, 2026" report provides comprehensive global coverage of the emerging therapeutic landscape for Scleroderma, highlighting pipeline therapies across various stages of development, key pharmaceutical and biotechnology companies actively advancing novel treatment approaches, and future opportunities expected to transform the Scleroderma treatment paradigm. The report delivers in-depth insights into disease biology, pipeline dynamics, therapeutic assessment, market drivers, barriers, and unmet needs shaping innovation within the Scleroderma space.

Key Takeaways from the Scleroderma Clinical Trial Landscape Report
• DelveInsight's Scleroderma pipeline report showcases a dynamic pipeline landscape with more than 25 therapies being evaluated across Discovery, Preclinical, Phase I, Phase I/II, Phase II, and Phase III stages of development.
• Key Scleroderma companies involved in therapeutic development include BIOCAD, Mitsubishi Tanabe Pharma Corporation, Cumberland Pharmaceuticals, Boehringer Ingelheim, Cabaletta Bio, Rubedo Life Sciences, Kyverna Therapeutics, Adicet Bio, and others.
• Promising Scleroderma pipeline therapies in development include Divozilimab, MT-0551, Ifetroban, BI 685509, CABA-201, RLS-1496, KYV-101, ADI-001, and others.
• The pipeline incorporates multiple innovative mechanisms of action, including Anti-CD20 monoclonal antibodies, Anti-CD19 CAR-T therapies, GPX4 modulators, sGC activators, Melanocortin type 1 receptor agonists, and Selective Thromboxane-Prostanoid Receptor antagonists.
• The therapeutic landscape reflects growing industry focus on addressing fibrosis, immune dysregulation, vascular abnormalities, and organ involvement associated with systemic sclerosis.

Request a sample and discover the latest advancements in Scleroderma treatment development.
https://www.delveinsight.com/sample-request/scleroderma-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Scleroderma?

Scleroderma, also known as systemic sclerosis, is a chronic autoimmune disorder characterized by excessive collagen production that leads to fibrosis of the skin and internal organs. The disease affects connective tissues and can involve multiple organ systems, including the lungs, heart, kidneys, and gastrointestinal tract. It is associated with vascular dysfunction, chronic inflammation, and autoantibody production. Scleroderma occurs predominantly in women, with a female-to-male ratio of approximately 4:1, and affects an estimated 150-300 individuals per million population.
Raynaud's phenomenon is among the most common early manifestations and occurs in approximately 90% of patients. Internal organ involvement, particularly affecting the lungs and gastrointestinal tract, occurs in approximately 30-50% of patients and contributes significantly to disease morbidity and mortality. Despite therapeutic advances, there is currently no cure for Scleroderma, and treatment remains focused on symptom management and prevention of disease progression.

Emerging Scleroderma Drug Profiles
Divozilimab: BIOCAD
Divozilimab (BCD-132) is a humanized anti-CD20 monoclonal antibody being developed by BIOCAD for the treatment of systemic sclerosis. The therapy selectively binds CD20-positive B lymphocytes and promotes B-cell depletion through antibody-dependent cellular cytotoxicity and complement-mediated cytotoxicity. This mechanism aims to reduce pathogenic immune activity and fibrosis associated with Scleroderma. Currently, Divozilimab is the most advanced pipeline candidate and is being evaluated in Phase III clinical development.
Results from a randomized, double-blind, placebo-controlled Phase III study demonstrated a statistically significant reduction in skin fibrosis severity. Patients receiving Divozilimab achieved a mean modified Rodnan Skin Score (mRSS) improvement of -5.8 points compared with -2.7 points in the placebo group. The therapy also demonstrated stabilization of lung function and a favorable safety profile, highlighting its potential as a promising treatment option for systemic sclerosis.
CABA-201: Cabaletta Bio
CABA-201 is an investigational Anti-CD19 CAR-T cell therapy being developed by Cabaletta Bio for patients with systemic sclerosis. The therapy is currently in Phase I/II clinical development and is designed to eliminate autoreactive B cells responsible for driving autoimmune pathology. By resetting the immune system, CABA-201 has the potential to provide durable disease control in patients with severe forms of systemic sclerosis.
BI 685509: Boehringer Ingelheim
BI 685509 is an investigational soluble guanylate cyclase (sGC) activator being evaluated in Phase II clinical development. The therapy is designed to improve vascular function and reduce fibrotic progression, addressing key pathogenic mechanisms associated with systemic sclerosis.
Ifetroban: Cumberland Pharmaceuticals
Ifetroban is a selective thromboxane-prostanoid receptor antagonist currently being evaluated in Phase II clinical development. The therapy aims to improve vascular complications and inflammatory processes associated with Scleroderma.

Recent Developments in the Scleroderma Clinical Trial Landscape
• In January 2026, Indero announced a strategic collaboration with the World Scleroderma Foundation (WSF) to support the WSF SHIELD adaptive platform clinical trial. The study is designed to evaluate multiple investigational therapies in patients meeting Very Early Diagnosis of Systemic Sclerosis (VEDOSS) criteria, with the objective of improving long-term patient outcomes through early intervention.
• In October 2025, Cabaletta Bio announced positive preliminary Phase I/II clinical data from six patients enrolled in the RESET-SSc study evaluating CABA-201. The update included encouraging findings from both severe skin and organ involvement cohorts.
• In July 2025, Adicet Bio announced dosing of the first systemic sclerosis patient in the second cohort of its Phase I study evaluating ADI-001 across multiple autoimmune diseases, including systemic sclerosis.
• BIOCAD continues to advance the Phase III development of Divozilimab following encouraging efficacy and safety findings demonstrating significant improvement in skin fibrosis and stabilization of pulmonary function among systemic sclerosis patients.

Scope of the Scleroderma Pipeline Report
• Coverage: Global
• Therapeutic Assessment by Product Type: Monotherapy and Combination Therapy
• Therapeutic Assessment by Clinical Stage: Discovery, Preclinical, Phase I, Phase I/II, Phase II, and Phase III
• Therapeutic Assessment by Route of Administration: Oral, Intravenous, Subcutaneous, Topical, and Others
• Therapeutic Assessment by Molecule Type: Monoclonal Antibodies, Small Molecules, Cell Therapies, and Others
• Key Companies: BIOCAD, Mitsubishi Tanabe Pharma Corporation, Cumberland Pharmaceuticals, Boehringer Ingelheim, Cabaletta Bio, Rubedo Life Sciences, Kyverna Therapeutics, Adicet Bio, and others
• Key Pipeline Therapies: Divozilimab, MT-0551, Ifetroban, BI 685509, CABA-201, RLS-1496, KYV-101, ADI-001, and others

Dive deep into comprehensive insights on emerging therapies, clinical trial developments, and future opportunities in the Scleroderma treatment landscape. https://www.delveinsight.com/sample-request/scleroderma-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. Scleroderma Pipeline Report Introduction
2. Scleroderma Pipeline Executive Summary
3. Scleroderma Overview
4. Pipeline Scenario
5. Scleroderma Background and Disease Overview
6. Signs and Symptoms
7. Diagnosis
8. Treatment Landscape
9. Pipeline Therapeutics
10. Comparative Analysis
11. Therapeutic Assessment
12. Assessment by Route of Administration
13. Assessment by Product Type
14. Assessment by Molecule Type
15. Mid-Stage Products
16. Early-Stage Products
17. Preclinical and Discovery Stage Products
18. Inactive Products
19. Licensing, Partnering and Funding Analysis
20. Unmet Needs
21. Market Drivers and Barriers
22. Future Perspectives
23. Analyst Views
24. References
25. Report Methodology
26. DelveInsight Capabilities
27. Disclaimer
28. About DelveInsight
For further information on Scleroderma pipeline therapeutics, reach out to DelveInsight. https://www.delveinsight.com/sample-request/scleroderma-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical and biotechnology companies by providing comprehensive end-to-end solutions that improve business performance. Get hassle-free access to healthcare and pharmaceutical market research reports through DelveInsight's subscription-based platform, PharmDelve.

This release was published on openPR.